Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3935-3943

  Ohtsu, Atsushi ^a   Ajani, Jaffer A ^d   Bai, Yu Xian ^f   Bang, Yung Jue ⁱ   Chung, Hyun Cheol ^j   Pan, Hong Ming ^g   Sahmoud, Tarek ^e   Shen, Lin ^h   Yeh, Kun Huei ^l   Chin, Keisho ^b   Muro, Kei ^c   Kim, Yeul Hong ^k   Ferry, David ^m   Tebbutt, Niall C ⁿ   Al Batran, Salah Eddin ^o   Smith, Heind ^e   Costantini, Chiara ^e   Rizvi, Syed ^e   Lebwohl, David ^e   Van Cutsem, Eric ^p  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f HARBIN MEDICAL UNIVERSITY   (China)

^g ZHEJIANG UNIVERSITY   (China)

^h PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

ⁱ Seoul National University College of Medicine   (South Korea)

^j Yonsei University College of Medicine   (South Korea)

^k Korea University College of Medicine   (South Korea)

^l NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^m NEW CROSS HOSPITAL   (United Kingdom)

ⁿ AUSTIN HEALTH   (Australia)

^o KRANKENHAUS NORDWEST   (Germany)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PLACEBO; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; DRUG DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; ASIA; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ETHNICITY; FATIGUE; FEMALE; FEVER; GASTRECTOMY; GASTROINTESTINAL HEMORRHAGE; HISPANIC; HUMAN; HYPOKALEMIA; INDIAN; INSOMNIA; JAPANESE; LIVER METASTASIS; LOWER ESOPHAGUS SPHINCTER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT HISTORY OF RADIOTHERAPY; PATIENT HISTORY OF SURGERY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; STOMACH CANCER; STOMATITIS; SUDDEN DEATH; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODEL; STOMACH NEOPLASMS; VERY ELDERLY; YOUNG ADULT; CONTROLLED CLINICAL TRIAL; STOMACH TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; SIROLIMUS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84891371392     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.3552     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (including cancer in the proximal 5cm of the stomach), version 2.2012. http://www.nccn.org/professionals/physician-gls/pdf/ gastric.pdf
3. Okines A, Verheij M, Allum W, et al: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v50-v54, 2010 (suppl 5)
4. Sasako M, Inoue M, Lin JT, et al: Gastric Cancer Working Group report. Jpn J Clin Oncol 40:i28-i37, 2010 (suppl 1)
5. Howlander N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2008. http://seer.cancer.gov/csr/1975-2008
6. Inoue M, Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad Med J 81:419-424, 2005 (Pubitemid 41002579)
7. Kim HS, Lee H, Jeung HC, et al: Advanced detection of recent changing trends in gastric cancer survival: Up-to-date comparison by period analysis. Jpn J Clin Oncol 41:1344-1350, 2011
8. Catalano V, Labianca R, Beretta GD, et al: Gastric cancer. Crit Rev Oncol Hematol 71:127-164, 2009
9. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
10. Wagner AD, Unverzagt S, Grothe W, et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3:CD004064, 2010
11. Thuss-Patience PC, Kretzschmar A, Bichev D, et al: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306-2314, 2011
12. Kang JH, Lee SI, Lim do H, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518, 2012
13. Oki E, Baba H, Tokunaga E, et al: Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 117:376-380, 2005 (Pubitemid 41429560)
14. Lang SA, Gaumann A, Koehl GE, et al: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803-1810, 2007 (Pubitemid 46399369)
15. Xu DZ, Geng QR, Tian Y, et al: Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 10:536, 2010
16. Yu G, Wang J, Chen Y, et al: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 15:1821-1829, 2009
17. An JY, Kim KM, Choi MG, et al: Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 126:2904-2913, 2010
18. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116:4256-4265, 2010
19. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
20. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
21. Franz DN, Belousova E, Sparagana S, et al: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicenter, randomised, placebo-controlled phase 3 trial. Lancet 381:125-132, 2013
22. Bissler JJ, Kingswood JC, Radzikowska E, et al: Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: A multicenter, randomized, doubleblind, placebo-controlled trial. Lancet 10.1016/S0140-6736(12)61767-X
23. Taguchi F, Kodera Y, Katanasaka Y, et al: Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 29:1198-1205, 2011
24. Jaeger-Lansky A, Cejka D, Ying L, et al: Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol Ther 9:919-927, 2010
25. Yeh KH, Chiang YW, Lin CS, et al: Chemosensitizing effects and sustained G1-S cell cycle arrest by low-dose RAD001 (everolimus) for cisplatin and 5-fluorouracil in human gastric cancer cells. Proc Am Assoc Cancer Res 58:957, 2007 (abstr 4043)
26. Cejka D, Preusser M, Fuereder T, et al: mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 28:3801-3808, 2008
27. Lee KH, Hur HS, Im SA, et al: RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 299:22-28, 2010
28. Doi T, Muro K, Boku N, et al: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28:1904-1910, 2010
29. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
30. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
31. National Cancer Institute: Cancer Therapy Evaluation Program: Common terminology criteria for adverse events, version 3.0, 2006. http://ctep.cancer. gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
32. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
33. Yoon DH, Ryu MH, Park YS, et al: Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106:1039-1044, 2012